{"id":98817,"date":"2026-06-22T05:00:47","date_gmt":"2026-06-22T03:00:47","guid":{"rendered":"https:\/\/www.veeva.com\/eu\/?p=98817"},"modified":"2026-07-17T16:33:49","modified_gmt":"2026-07-17T14:33:49","slug":"a-new-wave-of-clinical-data-innovation-faster-timelines-and-better-experiences","status":"publish","type":"post","link":"https:\/\/www.veeva.com\/eu\/blog\/a-new-wave-of-clinical-data-innovation-faster-timelines-and-better-experiences\/","title":{"rendered":"A New Wave of Clinical Data Innovation: Faster Timelines and Better Experiences"},"content":{"rendered":"

Each year<\/a> at ³Ô¹Ï±¬ÁÏ R&D and Quality Summit, biopharmas, sites, and CROs showcase how their organizations innovate and achieve efficiency amidst growing clinical trial complexity. This year, the momentum centered on a unified mission: breaking down silos to build a truly connected clinical ecosystem that elevates the trial experience for sponsors, CROs, sites, and, most importantly, patients. <\/p>\n

We shared key innovations<\/a> that will finally bridge the current gap between these stakeholders and address the lack of a global standard to connect and map clinical data. For example, with ³Ô¹Ï±¬ÁÏ eSource<\/a>, sites are in control of the technology and whether they choose to adopt it as their standard. This will help eSource adoption to scale where previous sponsor-owned (and imposed) tools have not.\n<\/p>\n

Risk-based quality management (RBQM)<\/a> is a capability that has been around for many years, but still with relatively low industry adoption. ³Ô¹Ï±¬ÁÏ RBQM will be delivered within ³Ô¹Ï±¬ÁÏ CTMS and ³Ô¹Ï±¬ÁÏ DQS without adding another system to the clinical technology landscape.<\/p>\n

Alex Franklin, director data management at GSK, said that, \u201cHaving ³Ô¹Ï±¬ÁÏ DQS as a center for data orchestration and high level management of risk \u2013 interlinking with different functions \u2013 gives a connected landscape that will provide oversight of the data. That value-driven cleaning in a risk-based approach will be key for assessing quality and driving change.\u201d<\/p>\n

By focusing on innovating for value, we will deliver three AI agents<\/strong> this year to automate processes across study build, testing, data collection, and data cleaning. These AI agent-based automations will help reduce burden for sites and data managers.\n<\/p>\n

\n
\n

“I\u2019m excited about ³Ô¹Ï±¬ÁÏ\u2019s AI vision; that you\u2019re leaning into new technology and doing it in a use case-based way.”<\/p>\n

\n
Product Director<\/h6>\n

Top 20 biopharma<\/p>\n<\/p><\/div>\n<\/p><\/div>\n<\/div>\n

These much anticipated innovations will add to the value now being achieved by the industry using the ³Ô¹Ï±¬ÁÏ Clinical Platform:<\/p>\n

Modernizing eCOA operations and site experiences<\/h2>\n

Fortrea<\/strong>: By changing ways of working, Fortrea is accelerating eCOA timelines and improving the user experience.<\/p>\n

Across their portfolio of ³Ô¹Ï±¬ÁÏ eCOA studies, Fortrea is delivering consistently with high patient compliance and de-risking the studies. Key results include:<\/p>\n